Select Bancorp Reports Third Quarter 2015 Earnings DUNN,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Select Bancorp Reports Third Quarter 2015 Earnings

DUNN, N.C., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Select Bancorp, Inc. (the “Company”)  (NASDAQ: SLCT ), the holding company for Select Bank & Trust, today reported net income of $1.4 million for the quarter ended September 30, 2015, and basic and diluted earnings per share of $0.12, compared to net income of $194,000 and basic and diluted earnings per share of $0.02 for the third quarter of 2014.  

Total assets, deposits, and total loans for the Company as of September 30, 2015, were $786.5 million, $619.9 million, and $598.0 million, respectively, compared to total assets of $785.0 million, total deposits of $644.1 million, and total loans of $546.5 million as of the same date in 2014.

Commenting on third quarter 2015 results, William L. Hedgepeth II, President and CEO stated, “Our results for the third quarter were impacted by one-time expenses related to our acquisition of new branch offices in Morehead City and Leland, N.C., the closing of our Burlington and Gibsonville, N.C. offices, and the closing of our Ramsey Street Office in Fayetteville, N.C. While the costs associated with these initiatives decreased the Company’s non-interest income for the quarter by approximately $412 thousand, we believe our branch network, and our Company, will be better positioned to enhance efficiency and customer convenience going forward. Our previously announced acquisition of two new branches, one in Morehead City and the other in Leland near Wilmington, has received all required regulatory approvals and is scheduled to close during December.  We are also pleased that the Company was able to report net income of approximately $1.4 million for the quarter, even after incurring the expense associated with these long-term investments in our franchise.”

For the nine months ended September 30, 2015, the Company recorded after-tax net income of $4.9 million compared to $1.8 million for the nine months ended September 30, 2014.  Year to date basic and diluted earnings per share of $0.43 compared to $0.13 per share for the nine months ended September 30, 2014.  Year to date return on average assets through September 30, 2015 is 0.87% (annualized) and year to date return on average equity is 6.50% (annualized), compared to 0.20% and 1.74%, respectively, for the nine months ended September 30, 2014.

Non-performing loans decreased to $10.9 million at September 30, 2015 from $11.9 million at December 31, 2014. Non-performing loans equaled 1.82% of loans at September 30, 2015, decreasing from 2.15% of loans at December 31, 2014. Foreclosed real estate equaled $1.6 million at December 31, 2014 and decreased to $1.0 million at September 30, 2015.  For the quarter, recoveries were $107,000 or -0.02% of average loans, compared to a recovery of $139,000 or -0.10% of average loans in the fourth quarter of 2014. At September 30, 2015, the allowance for loan losses was $7.0 million or 1.18% of total loans, as compared to $6.8 million or 1.24% of total loans at December 31, 2014.

Mr. Hedgepeth concluded, "We are pleased with the Company’s year to date results of operations and continued asset quality and we look forward to bringing our ‘common sense banking’ to Morehead City and Leland before year end.  We continue to believe that Select is well positioned for the remainder of 2015 and beyond."

Select Bank & Trust has branch offices in these North Carolina communities: Dunn, Burlington, Clinton, Elizabeth City, Fayetteville, Goldsboro, Greenville, Lillington, Lumberton, Raleigh and Washington.

The information as of and for the quarter ended September 30, 2015, as presented is unaudited. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements regarding certain of our goals and expectations with respect to earnings, earnings per share, revenue, expenses and the growth rate in such items, as well as other measures of economic performance, including statements relating to estimates of credit quality trends, and (ii) statements preceded by, followed by or that include the words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “projects,” “outlook” or similar expressions. The actual results might differ materially from those projected in the forward-looking statements for various reasons, including, but not limited to, our ability to manage growth, substantial changes in financial markets, regulatory changes, changes in interest rates, loss of deposits and loan demand to other savings and financial institutions, and changes in real estate values and the real estate market. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in the Company’s SEC filings, including its periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from the Company.

Select Bancorp, Inc.
Selected Financial Information and Other Data
($ in thousands, except per share data)
                 
  At or for the three months ended   At or for the twelve months ended  
    September 30, 2015     June 30,  2015     March 31,  2015     December 31, 2014     September 30,  2014     December 31, 2014     December 31, 2013     December 31, 2012  
Summary of Operations:                                                
Total interest income $ 8,412   $ 8,262   $ 8,242   $ 7,988   $ 7,541   $ 26,104   $ 22,903   $ 25,132  
Total interest expense   878     835     939     1,141     1,169     4,519     5,258     6,632  
Net interest income   7,534     7,427     7,303     6,847     6,372     21,585     17,645     18,500  
Provision for (recovery of) loan losses   393     (139 )   130     177     105     (194 )   (325 )   (2,597 )
Net interest income after provision   7,141     7,566     7,173     6,670     6,267     21,779     17,970     21,097  
Noninterest income   572     941     863     836     650     2,675     2,629     3,598  
Merger/Acquisition related expenses   103     35     -     217     1,325     1,941     -     -  
Noninterest expense   5,467     5,518     5,370     5,345     5,168     18,719     15,855     17,236  
Income before income taxes   2,143     2,954     2,666     1,944     424     3,794     4,744     7,459  
Provision for income taxes   792     1,133     923     666     230     1,437     1,803     2,822  
Net Income   1,351     1,821     1,743     1,278     194     2,357     2,941     4,637  
Dividends on Preferred Stock   19     19     19     19     19     38     -     -  
Net income available to common shareholders $ 1,332   $ 1,802   $ 1,724   $ 1,259   $ 175   $ 2,319   $ 2,941   $ 4,637  
                                                 
Share and Per Share Data:                
Earnings per share - basic $ 0.12   $ 0.16   $ 0.15   $ 0.11   $ 0.02   $ 0.26   $ 0.43   $ 0.67  
Earnings per share - diluted $ 0.12   $ 0.16   $ 0.15   $ 0.11   $ 0.02   $ 0.26   $ 0.43   $ 0.67  
Book value per share $ 8.28   $ 8.17   $ 8.07   $ 7.91   $ 7.61   $ 8.59   $ 8.09   $ 7.84  
Tangible book value per share $ 7.58   $ 7.45   $ 7.33   $ 7.16   $ 7.01   $ 7.83   $ 8.07   $ 7.79  
Ending shares outstanding   11,577,111     11,499,398     11,458,561     11,377,980     11,349,368     11,377,980     6,921,352     6,913,636  
Weighted average shares outstanding:                
Basic   11,521,043     11,481,137     11,426,378     11,375,803     10,195,846     8,870,114     6,918,814     6,898,147  
Diluted   11,582,724     11,548,878     11,510,147     11,475,865     10,312,085     8,974,384     6,919,760     6,898,377  
                 
Selected Performance Ratios:                
Return on average assets (2)   0.69 %   0.98 %   0.94 %   0.65 %   0.10 %   0.37 %   0.53 %   0.81 %
Return on average equity (2)   5.21 %   7.22 %   7.11 %   5.23 %   0.82 %   3.12 %   5.28 %   8.79 %
Net interest margin   4.34 %   4.46 %   4.30 %   3.87 %   3.99 %   3.88 %   3.46 %   3.57 %
Efficiency ratio (1)   67.44 %   65.94 %   65.76 %   69.57 %   73.60 %   77.16 %   78.20 %   78.00 %
                 
Period End Balance Sheet Data:                
Loans, net of unearned income $ 597,969   $ 573,729   $ 558,923   $ 552,038   $ 546,475   $ 552,038   $ 346,500   $ 367,891  
Total Earning Assets   711,622     665,028     663,017     698,266     710,005     698,266     483,054     543,674  
Goodwill   6,931     6,931     6,931     6,931     6,931     6,931     -     -  
Core Deposit Intangible   1,196     1,320     1,470     1,625     1,786     1,625     182     298  
Total Assets   786,495     742,443     748,371     766,121     784,983     766,121     525,646     585,453  
Deposits   619,935     579,609     600,520     618,902     644,093     618,902     448,458     498,559  
Short term debt   30,722     32,884     18,943     20,733     18,077     20,733     6,305     17,848  
Long term debt   28,846     24,914     25,282     25,591     26,049     25,591     12,372     12,372  
Shareholders' equity   103,545     101,552     100,076     97,685     93,995     97,685     56,004     54,179  
                 
Selected Average Balances:                
Gross Loans $ 585,541   $ 569,785   $ 557,177   $ 546,626   $ 489,563   $ 430,571   $ 354,871   $ 391,648  
Total Earning Assets   689,166     669,586     672,655     702,818     632,922     565,264     511,597     532,193  
Core Deposit Intangible   1,251     1,389     1,546     1,714     1,496     884     237     389  
Total Assets   771,913     744,118     748,047     776,839     709,480     631,905     555,354     574,616  
Deposits   607,722     588,328     600,601     632,633     582,825     523,954     470,526     481,387  
Short term debt   35,012     28,212     19,298     19,790     14,652     9,957     13,879     17,848  
Long term debt   22,631     22,895     25,444     25,818     22,343     20,494     12,372     12,372  
Shareholders' equity   102,879     101,216     99,376     97,030     84,744     74,365     55,701     52,769  
                 
Asset Quality Ratios:                
Nonperforming loans $ 10,899   $ 11,702   $ 13,473   $ 11,876   $ 12,375   $ 11,876   $ 15,856   $ 12,030  
Other real estate owned   1,007     1,030     1,187     1,585     1,687     1,585     2,008     2,833  
Allowance for loan losses   7,032     6,842     6,919     6,844     6,529     6,844     7,054     7,897  
Nonperforming loans (3) to period-end loans   1.82 %   2.04 %   2.41 %   2.15 %   2.26 %   2.15 %   4.58 %   3.27 %
Allowance for loan losses to period-end loans   1.18 %   1.19 %   1.24 %   1.24 %   1.19 %   1.24 %   2.04 %   2.15 %
Delinquency Ratio (4)   0.36 %   0.32 %   0.23 %   0.91 %   0.36 %   0.91 %   0.25 %   0.32 %
Net loan charge-offs (recoveries) to average loans   0.14 %   -0.01 %   0.04 %   -0.10 %   0.02 %   -0.03 %   0.15 %   -0.12 %
                 
(1) Efficiency ratio is calculated as non-interest expenses divided by the sum of net interest income and non-interest income.
(2) Annualized.
(3) Nonperforming loans consist of non-accrual loans and restructured loans.
(4) Delinquency Ratio includes loans 30-89 days past due and excludes non-accrual loans.
 

CONTACT: Mark A. Jeffries Executive Vice President Chief Financial Officer Office: 910-892-7080 and Direct: 910-897-3603 markj@SelectBank.com SelectBank.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DAN, GPRO, PSNL Deals Under Investor Scrutiny

Updated Category News Views 40

Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...

Continue Reading
Raytron Dominates Global Thermal Imaging Market in 2026

Updated Category News Views 106

Raytron's Market Supremacy: By the Numbers If you're looking at the thermal imaging sector and wondering what's what, take a clue from Raytron. This outfit isn't just playing the game—it's running the show with a staggering 30% of the global market in 2025. That's right, they hold the medal for leading global shipments in thermal imaging, and unlike many industries...

Continue Reading
Asphalt Additives Market Set for $7.07B Boom by 2031

Updated Category News Views 65

Asphalt Additives: A Lucrative Growth Path Let me tell you, the asphalt additives market isn't just sticking to the roads; it's rolling out real potential. Heading for a $7.07B finish line by 2031 with a steady pace of 7.3% CAGR, it's a road worth staking your claims on. The underlying story? It's more than just laying tar. Pavement to Profit: Key Drivers The asphalt...

Continue Reading
Pearl Meyer Leaders Grab NACD's Coveted Governance Honor

Updated Category News Views 26

NACD Recognition for Governance Grit Some folks just know how to steer a ship, and that's exactly what Pearl Meyer's Matt Turner and Jannice Koors have been doing. This year, they made it onto the NACD's 2026 Directorship 100 list, swinging as heavy hitters in the Governance Professionals category. It's not just another day at the office when you're honored by the...

Continue Reading
Epson Unveils Early Black Friday Tech Deals

Updated Category News Views 69

Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...

Continue Reading
Doximity's Legal Woes: Class Action Deadline Looms

Updated Category News Views 15

The Truth Behind Doximity's Promises The brass tacks of investing often boil down to trust—a commodity that's now in short supply over at Doximity, Inc. (NYSE: DOCS). Investors have been left hanging after promises of lucrative engagement signals turned out to be a mere pipe dream. Levi & Korsinsky, LLP sounds the alarm on what's shaping up to be a high-stakes class...

Continue Reading
Insulin Delivery Devices: A Billion-Dollar Surge

Updated Category News Views 20

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Terra-Gen's $950M Lockhart Facility Powers California

Updated Category News Views 128

A New Giant in California's Solar Landscape Out in California's desert, Terra-Gen has flipped the switch on something pretty colossal: the $950 million Lockhart Solar and Storage Project. Picture this—a solar beast boasting 538.7 MW of capacity, primed to light up around 350,000 homes and businesses. That's not just flipping a light switch; that's sparking a fire that...

Continue Reading
Defense Contractors Push Forward Amid Indictments

Updated Category News Views 18

The Big Names Hold Steady Defense contractors are showing off their shiny earnings just as some disturbing headlines shake things up. It's like they're putting their best foot forward to steady the ship while the waters get choppy with terrorism charges and all sorts of geopolitical noise. Follow the smart money to see where the true bets are being placed—it all unfolds...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading